Most recent by Douglas Yee, MD
De-escalated neoadjuvant paclitaxel, dual HER2 blockade effective in breast cancer subtype
A de-escalated, 12-week neoadjuvant treatment regimen of dual HER2 blockade with pertuzumab and trastuzumab plus weekly paclitaxel demonstrated high efficacy among patients with HER2-positive, hormone receptor-negative early breast cancer.
Neoadjuvant therapy provides opportunity to discover new treatment strategies
Adjuvant breast cancer therapies historically have been performed as postsurgical treatment.
TAILORx ‘shows path’ to de-escalate therapy for some women, raises treatment questions for others
Adjuvant therapy of breast cancer has unquestionably resulted in improved survival for women with operable breast cancer.
Neoadjuvant studies can demonstrate value of new agents in breast cancer
Presurgical systemic — or neoadjuvant — therapy has been shown to induce pathologic complete response (pCR) rates in a substantial number of women with operable breast cancer.
Study results guide decisions about local therapy for breast cancer
Agarwal and colleagues analyzed the SEER database from 1998 to 2008 to address a common question posed by many patients: “Wouldn’t it be better to have my breasts removed to prevent recurrence?”
Can we save money by spending more? A case for cancer research
“You can’t always get what you want, but if you try sometimes, you just might find, you get what you need.”